LifeMD, Inc. (LFMD)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-04
$2.29-6.53%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-04
QuarterlyIQ Insights · LFMD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -66.3% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 23.7% |
Growth built into the price is above our model estimate.
The price assumes 90.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 9 industry peers
LFMD — earnings miss
Dated 2026-05-06
Results of Operations and Financial Condition. On May 6, 2026, LifeMD, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
Why it matters: Management tied this Q4 range to a roughly $250 million annualized revenue run rate. A miss would weaken that target.
Watch forThe Q4 report shows revenue of at least $60 million and no more than $64 million.
Also watch forQ4 revenue is below $60 million or above $64 million.
Why it matters: LifeMD launched the program in 37 states. Updates on reach or patient use can show whether this new care and pharmacy channel is gaining ground.
Supportive ifLifeMD reports expansion beyond 37 states or gives a rising count of XYOSTED patients or refills.
Worry ifLifeMD reports a launch delay, a state-count decline, or no patient or refill growth in a later update.
Why it matters: Q2 revenue was $47.3 million, and full-year revenue guidance fell. Q3 tests whether revenue is back on track.
Watch forIn the November 9, 2026 earnings report, Q3 revenue is at least $48 million and no more than $51 million.
Also watch forQ3 revenue is below $48 million or above $51 million.
Why it matters: The AT&T deal starts in a limited number of states, then may expand nationwide. Wider access could bring LifeMD new members.
Supportive ifLifeMD or AT&T announces the program is live in more states than at launch, or confirms access across the country.
Worry ifA company update says the launch is delayed, remains limited, or will not expand as planned.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$255 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $720 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,306 loss on $10,000 · 63.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Active subscribers fell from about 365,000 in Q1 to 356,000 in Q2, even as they grew year over year. The next report tests the trend.
Watch forThe November 9 report shows more than 356,000 active subscribers.
Also watch forThe November 9 report shows active subscribers at or below 356,000.
Why it matters: LifeMD reported a $3.5 million Q2 adjusted EBITDA loss. A positive Q3 result would show progress toward its second-half goal.
Watch forThe November 9 report shows Q3 adjusted EBITDA above $0. It is within the guided range of negative $1 million to positive $2 million.
Also watch forQ3 adjusted EBITDA is less than negative $1 million.